• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MUSC Health and Baxter Announce Strategic Partnership to Transform Bedside Care Delivery and Address Critical Nursing Challenges

    1/8/26 9:00:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care
    Get the next $BAX alert in real time by email

    MUSC Health and Baxter International Inc. (NYSE:BAX), a global medtech leader, are entering into a multi-year strategic partnership that aims to enhance the high-quality and safe patient care already delivered at MUSC Health, MUSC's health care system, through integrated connected care technologies.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108293816/en/

    By leveraging Baxter's cutting-edge solutions and MUSC Health's clinical and academic expertise, the partnership aims to help drive further improvements in nurse satisfaction and retention, elevate quality and safety outcomes, and pave the way for future innovations in care delivery. The partnership also aims to serve as a platform for new approaches, including automating and building actionable outcomes into nursing workflows across the care continuum, as well as evaluating outcomes and sharing best practices that can be scaled across the broader healthcare industry.

    "This partnership represents a shared commitment to supporting our nurses – who are the backbone of patient care – with the tools, technology and training they need to thrive," said Patrick J. Cawley, M.D., CEO, MUSC Health and executive vice president for Health Affairs, University. "Together with Baxter, we are building a model that will not only impact the day-to-day experience for our caregivers but also further enhance the exceptional care we provide to patients across the state."

    "As a nurse, I have seen firsthand the significant administrative burden that so many of my colleagues face every day. These challenges can take time away from what matters most – spending time at the bed side with patients," said Baley Ganger, Chief Nursing Information Officer, MUSC Health. "I am excited to see how our strategic partnership with Baxter and the integration of connected technologies will help alleviate these burdens, allowing nurses to focus on providing excellent patient care."

    Key objectives of the partnership include:

    • Further standardizing and simplifying connected technologies at the bedside to reduce documentation time, streamline communication and help ensure seamless data integration across systems.
    • Improving nurse workforce satisfaction and retention by alleviating administrative burdens and empowering clinical teams with smart and intuitive tools.
    • Enhancing quality and safety outcomes through real-time insights, advanced monitoring, and data-driven decision-making.
    • Driving nursing education through collaborative initiatives that will shape the future of nursing care.

    "Continuously improving the experiences of care teams with our connected technologies and services is at the core of Baxter's vision to redefine healthcare delivery," said Reaz Rasul, executive vice president and group president of Baxter's Healthcare Systems & Technologies segment. "We are honored to partner with MUSC Health to help create scalable, innovative solutions that further support improved care outcomes and help nurses focus on what matters most: patient care."

    About MUSC

    Founded in 1824 in Charleston, MUSC is the state's only comprehensive academic health system, with a mission to preserve and optimize human life in South Carolina through education, research and patient care. Each year, MUSC educates over 3,300 students in six colleges and trains more than 1,060 residents and fellows across its health system. MUSC leads the state in federal, National Institutes of Health and other research funding. For information on our academic programs, visit MUSC.edu.

    As the health care system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest-quality and safest patient care while educating and training generations of outstanding health care providers and leaders to serve the people of South Carolina and beyond. In 2025, for the 11th consecutive year, U.S. News & World Report named MUSC Health University Medical Center in Charleston the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit MUSCHealth.org.

    MUSC has a total enterprise annual operating budget of $8.2 billion. The nearly 34,000 MUSC members include world-class faculty, physicians, specialty providers, scientists, contract employees, affiliates and care team members who deliver groundbreaking education, research and patient care.

    About Baxter

    At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately 38,000 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260108293816/en/

    Media Contacts:

    For MUSC:

    Kristin Merkel

    C. 854-253-9926

    [email protected]

    For Baxter:

    Andrea Johnson

    224-948-5353

    [email protected]

    Get the next $BAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX

    DatePrice TargetRatingAnalyst
    10/31/2025Buy → Hold
    Argus
    8/4/2025$25.00Buy → Hold
    Stifel
    8/1/2025$25.00Buy → Neutral
    Goldman
    2/26/2025$42.00Buy
    Goldman
    2/24/2025Hold → Buy
    Argus
    2/20/2025$39.00Overweight
    Barclays
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    5/30/2024$36.00Neutral
    Goldman
    More analyst ratings

    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MUSC Health and Baxter Announce Strategic Partnership to Transform Bedside Care Delivery and Address Critical Nursing Challenges

    MUSC Health and Baxter International Inc. (NYSE:BAX), a global medtech leader, are entering into a multi-year strategic partnership that aims to enhance the high-quality and safe patient care already delivered at MUSC Health, MUSC's health care system, through integrated connected care technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108293816/en/ By leveraging Baxter's cutting-edge solutions and MUSC Health's clinical and academic expertise, the partnership aims to help drive further improvements in nurse satisfaction and retention, elevate quality and safety outcomes, and pave the way for future innovations in c

    1/8/26 9:00:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter to Present at J.P. Morgan 2026 Healthcare Conference

    Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026. Andrew Hider, Baxter's president and chief executive officer, is scheduled to present at 2:15 p.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Saturday, July 11, 2026. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions

    1/6/26 5:14:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity

    Data shared in collaboration with The University of Texas Medical Branch, representing an analysis of more than one million intravenous (IV) infusions using Baxter's Spectrum IQ large volume infusion pumps (LVP) Evaluation of pre- and post-smart pump EMR integration data showed a reduction in patient safety alerts, time spent to program an infusion and to resolve a pump alert Findings underscore the potential role of connected infusion therapy in supporting patient safety, addressing clinician burnout and compliance Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced data in collaboration with The University of Texas Medi

    12/11/25 8:30:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    SEC Filings

    View All

    Baxter International Inc. filed SEC Form 8-K: Other Events

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    12/22/25 4:59:44 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    12/4/25 4:15:43 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    11/25/25 4:45:37 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Baxter downgraded by Argus

    Argus downgraded Baxter from Buy to Hold

    10/31/25 8:47:22 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Stifel with a new price target

    Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00

    8/4/25 8:18:58 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Goldman with a new price target

    Goldman downgraded Baxter from Buy to Neutral and set a new price target of $25.00

    8/1/25 8:11:11 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief HR Officer Mason Jeanne K covered exercise/tax liability with 650 shares, decreasing direct ownership by 0.32% to 199,853 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    12/16/25 4:06:15 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    New insider Soriano Maria Cecilia claimed ownership of 54,623 shares (SEC Form 3)

    3 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    12/10/25 9:18:08 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Baxter International Inc.

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    12/3/25 4:04:17 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Leadership Updates

    Live Leadership Updates

    View All

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Amerant Bancorp Announces Appointment of Two New Board Members

    Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe

    6/24/25 9:20:00 AM ET
    $AMTB
    $BAX
    $WBS
    Major Banks
    Finance
    Medical/Dental Instruments
    Health Care

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Baxter International Inc. (Amendment)

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 5:00:53 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Baxter International Inc.

    SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 1:08:57 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Financials

    Live finance-specific insights

    View All

    Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes. Title of Security CUSIP Number(1) Principal Amount Outstanding U.S. Treasury Reference Security Bloomberg Reference Page Reference Yield Fixed Spread Early Tender Payment (3)(4) Total Consideration(3)(4) 2.600% Senior Unsecured Notes due 2026 071813BQ1 $750,000,000 UST 1.500% due Aug. 15, 2026 FIT3 3.713% +30 bps $30

    12/4/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Announces Early Tender Results for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the early tender results for the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The tender offers are being made pursuant to the terms and conditions set forth in the offer to purchase, dated Nov. 19, 2025, as amended by the Company's press release dated Nov. 19, 2025 (as it may be further amended or supplemented from time to time, the "Offer to Purchase"). The tender offers comprise Baxter's offer to purchase for cash (a) any and all of its 2.600% senior unsecured notes due 2026 (the "2026 Notes") (the "Any and All Tender Offer") and (b) a portion of its 1.9

    12/4/25 7:51:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Announces Increase in Maximum Tender Cap for 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the "2027 Notes Tender Offer") from $300 million to $600 million, on the terms and subject to the conditions set forth in the related Offer to Purchase dated Nov. 19, 2025 (the "Offer to Purchase"). The terms of the previously announced cash tender offer by Baxter for its 2.600% Senior Unsecured Notes due 2026 (the "2026 Notes Tender Offer" and, togethe

    11/19/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care